Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Janssen Research & Development, LLC
Genmab
Genmab
Memorial Sloan Kettering Cancer Center
Georgetown University
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Acerta Pharma BV
AbbVie
Acerta Pharma BV
Acerta Pharma BV
Dana-Farber Cancer Institute
AstraZeneca
AbbVie
M.D. Anderson Cancer Center
Fate Therapeutics
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Gruppo Italiano Malattie EMatologiche dell'Adulto
Merck Sharp & Dohme LLC
Galapagos NV
Merck Sharp & Dohme LLC
BeOne Medicines
AstraZeneca
M.D. Anderson Cancer Center
BeOne Medicines
M.D. Anderson Cancer Center
University of Washington
AstraZeneca
Allogene Therapeutics
BeOne Medicines
M.D. Anderson Cancer Center
Eli Lilly and Company
AstraZeneca
Dana-Farber Cancer Institute